|
An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients Clinical research trials and An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients. An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients clinical trial. Participants oftentimes recieve the finest healthcare available for their An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients  An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients
An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients
For Condition: HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) , Connaught Laboratories
Synopsis: To determine, in HIV-infected patients, the magnitude and duration of the biological effects of ditiocarb sodium (sodium diethyldithiocarbamate; DTC) that may be relevant to treatment of HIV infection. DTC has been studied in previous clinical trials in HIV-infected patients with the suggestion of delay in disease progression to AIDS and improvement in CD4 counts while on the drug.
Details: DTC has been studied in previous clinical trials in HIV-infected patients with the suggestion of delay in disease progression to AIDS and improvement in CD4 counts while on the drug. Two groups of patients, one group asymptomatic and the other with AIDS diagnosis, are enrolled in the study. All patients receive DTC intravenously once a week for two weeks. Drugs are given on days 1 and 8. Blood samples are drawn on days 1, 3, 5, 8, 10, and 12.
Eligibility:
Study Type: Interventional, Treatment, Open Label
Minimum Age/Maximum Age: 18 Years/50 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must: - Have HIV infection. - Be asymptomatic (group 1) or have AIDS (group 2). - Be able to understand and follow instructions. Concurrent Medication: Allowed: GROUP 2: - Anti-HIV therapy. - Systemic prophylaxis or maintenance therapy for any AIDS-defining opportunistic infection excluding agents considered immunomodulators or immunosuppressants. - Topical nystatin. - Clotrimazole troches. - Acyclovir. - Dapsone. - Trimethoprim / sulfamethoxazole (T/S). - Fluconazole. - Ketoconazole. - Aerosolized pentamidine. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: ALL PATIENTS: - Known hypersensitivity to disulfiram or diethyldithiocarbamate (DTC). - Transfusion dependence. GROUP 1 PATIENTS ONLY: - Oral candidiasis documented by morphology or by a response to antifungal therapy. - Oral hairy leukoplakia. - Occurrence of herpes zoster in a single dermatomal distribution. - Recurrent seborrheic dermatitis. - Unintentional weight loss in excess of 10 pounds or 10 percent of usual body weight within 2 years prior to study. - Unexplained temperature above 38 degrees C on more than 5 consecutive days or on more than 10 days in any 30 days within 2 years of expected study entry. - Unexplained diarrhea defined by two or more stools/day for at least 14 days during a 120-day interval. - Evidence of clinically significant cardiac, respiratory, hepatic, gastrointestinal, endocrine, hematologic, psychiatric, neurologic, renal, or dermatologic disease as demonstrated by history, physical, and laboratory evaluation. GROUP 2 PATIENTS ONLY: - Concurrent neoplasms other than Kaposi's sarcoma or basal cell carcinoma of the skin. - Diagnosis of an acute opportunistic infection within 3 weeks of study entry or had treatment initiated for an opportunistic infection within 3 weeks of study entry. Concurrent Medication: Excluded: ALL PATIENTS: - Recombinant erythropoietin. GROUP 1: - Antiretroviral medications. GROUP 2: - Immunomodulators or immunosuppressants. Concurrent Treatment: Excluded: - Requirement for blood transfusions more than once a month. Patients with the following prior conditions are excluded: GROUP 1 PATIENTS ONLY: - Oral candidiasis documented by morphology or by a response to antifungal therapy. - Oral hairy leukoplakia. - Occurrence of herpes zoster in a single dermatomal distribution. - Recurrent seborrheic dermatitis. - Unintentional weight loss in excess of 10 pounds or 10 percent of usual body weight within 2 years prior to study. - Unexplained temperature above 38 degrees C on more than 5 consecutive days or on more than 10 days in any 30-day period within 2 years of expected study entry. - Unexplained diarrhea defined by two or more stools/day for at least 14 days during a 120-day interval. - Evidence of clinically significant cardiac, respiratory, hepatic, gastrointestinal, endocrine, hematologic, psychiatric, neurologic, renal, or dermatologic disease as demonstrated by history, physical, and laboratory evaluation. GROUP 2 PATIENTS ONLY: - Diagnosis of an acute opportunistic infection within 3 weeks of study entry or had treatment initiated for an opportunistic infection within 3 weeks of study entry. Prior Medication: Excluded: ALL PATIENTS: - Corticosteroids, cytotoxic agents, or immunomodulating agents within 30 days prior to study entry. - Chronic Antabuse (disulfiram) therapy. GROUP 1 ONLY: - Antiretrovial medications within 1 week prior to study entry. Prior Treatment: Excluded: - Transfusion within 7 days of study entry. - Radiation therapy within 30 days prior to study entry. Unable to refrain from the use of alcohol for the duration of the study.
Total Enrollment: 12
Location and Contact Information:
Overall Study Official:
PSLietman, Study Chair,
Johns Hopkins Hosp
Baltimore, Maryland, 21287
United States
Additional Information:
Study ID Numbers: ACTG 166;
Study Start Date:
Record last reviewed: March 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000650
Other Hiv Infections Studies:
1. Safety and Effectiveness of Emtricitabine Taken Once Daily with Efavirenz and Didanosine in HIV-Infected Children Who Have Taken Few or No Anti-HIV Drugs
2. A Comparison of the Safety and Effectiveness of Fluconazole or Clotrimazole in the Treatment of Fungal Infections of the Mouth and Throat in Patients with AIDS
3. A Comparison of BMS-232632 with Efavirenz, Each in Combination with Zidovudine-Lamivudine
4. An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent
5. Safety and Antifungal Activity of Recombinant Interferon-gamma 1b (rIFN-gamma 1b) Given with Standard Therapy in Patients with Cryptococcal Meningitis
Related Studies:
Other HIV Infections Clinical Trials
Other Maryland Clinical Trials
Other Baltimore Clinical Trials
An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients
|
|
|
|
|
|
|
|
